185 related articles for article (PubMed ID: 19923884)
1. Reevaluating cathepsin D as a biomarker for breast cancer: serum activity levels versus histopathology.
Abbott DE; Margaryan NV; Jeruss JS; Khan S; Kaklamani V; Winchester DJ; Hansen N; Rademaker A; Khalkhali-Ellis Z; Hendrix MJ
Cancer Biol Ther; 2010 Jan; 9(1):23-30. PubMed ID: 19923884
[TBL] [Abstract][Full Text] [Related]
2. Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis.
Jeschke U; Mylonas I; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2005; 25(3A):1615-22. PubMed ID: 16033070
[TBL] [Abstract][Full Text] [Related]
3. Elucidating the function of secreted maspin: inhibiting cathepsin D-mediated matrix degradation.
Khalkhali-Ellis Z; Hendrix MJ
Cancer Res; 2007 Apr; 67(8):3535-9. PubMed ID: 17440060
[TBL] [Abstract][Full Text] [Related]
4. Biological and clinical significance of cathepsin D in breast cancer.
Rochefort H
Acta Oncol; 1992; 31(2):125-30. PubMed ID: 1622626
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin D in breast cancer tissue.
Gonzalez Gancedo P; G-Casaus ML; Ruiz Cacho J; Calero F; Inocente JM; Gomez-Pastrana F; Ramon N
Int J Biol Markers; 1990; 5(4):203-6. PubMed ID: 1965545
[TBL] [Abstract][Full Text] [Related]
6. In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells.
Briozzo P; Morisset M; Capony F; Rougeot C; Rochefort H
Cancer Res; 1988 Jul; 48(13):3688-92. PubMed ID: 3378211
[TBL] [Abstract][Full Text] [Related]
7. Western immunoblotting and enzymatic activity analysis of cathepsin D in human breast cancer cell lines of different invasive potential. Regulation by 17beta-estradiol, tamoxifen and ICI 182,780.
Couissi D; Dubois V; Remacle C; Schonne E; Trouet A
Clin Exp Metastasis; 1997 Jul; 15(4):349-60. PubMed ID: 9219723
[TBL] [Abstract][Full Text] [Related]
8. Proteolysis of cystatin C by cathepsin D in the breast cancer microenvironment.
Laurent-Matha V; Huesgen PF; Masson O; Derocq D; Prébois C; Gary-Bobo M; Lecaille F; Rebière B; Meurice G; Oréar C; Hollingsworth RE; Abrahamson M; Lalmanach G; Overall CM; Liaudet-Coopman E
FASEB J; 2012 Dec; 26(12):5172-81. PubMed ID: 22898924
[TBL] [Abstract][Full Text] [Related]
9. Cathepsin D detected by automated and quantitative immunohistochemistry in breast carcinomas: correlation with overall and disease free survival.
Charpin C; Garcia S; Bouvier C; Martini F; Lavaut M; Allasia C; Bonnier P; Andrac L
J Clin Pathol; 1997 Jul; 50(7):586-90. PubMed ID: 9306940
[TBL] [Abstract][Full Text] [Related]
10. Cathepsin D expression in skin metastasis of breast cancer.
Inoue H; Kawada A; Takasu H; Maruyama R; Hata Y; Hiruma M; Tajima S; Ishibashi A
J Cutan Pathol; 1998 Aug; 25(7):365-9. PubMed ID: 9765021
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of cathepsin D as prognostic predictor in breast cancer.
Barbi GP; Margallo E; Margiocco M; Paganuzzi M; Marroni P; Costanzi B; Gatteschi B; Tanara G; Spina B; Nicolò G
Oncology; 1994; 51(4):329-33. PubMed ID: 8208515
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of cathepsin D in breast cancer: comparison of immunohistochemical and immunoradiometric detection methods.
Göhring UJ; Scharl A; Thelen U; Ahr A; Crombach G; Titius BR
J Clin Pathol; 1996 Jan; 49(1):57-64. PubMed ID: 8666688
[TBL] [Abstract][Full Text] [Related]
13. Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence.
Kute TE; Grøndahl-Hansen J; Shao SM; Long R; Russell G; Brünner N
Breast Cancer Res Treat; 1998 Jan; 47(1):9-16. PubMed ID: 9493971
[TBL] [Abstract][Full Text] [Related]
14. Cathepsin D in breast cancer cells can digest extracellular matrix in large acidic vesicles.
Montcourrier P; Mangeat PH; Salazar G; Morisset M; Sahuquet A; Rochefort H
Cancer Res; 1990 Sep; 50(18):6045-54. PubMed ID: 2393869
[TBL] [Abstract][Full Text] [Related]
15. Analysis of cathepsin D in human breast cancer: usefulness of the processed 31 kDa active form of the enzyme as a prognostic indicator in node-negative and node-positive patients.
Riley LB; Lange MK; Browne RJ; Cochrane PJ; Choi IJ; Davis B; Arcona S; Alhadeff JA
Breast Cancer Res Treat; 2000 Mar; 60(2):173-9. PubMed ID: 10845280
[TBL] [Abstract][Full Text] [Related]
16. Expression of cathepsin-D in primary breast cancer and corresponding local recurrence or metastasis: an immunohistochemical study.
Dian D; Vrekoussis T; Shabani N; Mylonas I; Kuhn C; Schindlbeck C; Navrozoglou I; Friese K; Makrigiannakis A; Jeschke U
Anticancer Res; 2012 Mar; 32(3):901-5. PubMed ID: 22399610
[TBL] [Abstract][Full Text] [Related]
17. Cathepsin D in breast cancer.
Rochefort H
Breast Cancer Res Treat; 1990 Jul; 16(1):3-13. PubMed ID: 2207345
[TBL] [Abstract][Full Text] [Related]
18. Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview.
Rochefort H; Garcia M; Glondu M; Laurent V; Liaudet E; Rey JM; Roger P
Clin Chim Acta; 2000 Feb; 291(2):157-70. PubMed ID: 10675721
[TBL] [Abstract][Full Text] [Related]
19. The dilemma: does tissue expression of cathepsin D reflect tumor malignancy? The question: does the assay truly mirror cathepsin D mis-function in the tumor?
Nicotra G; Castino R; Follo C; Peracchio C; Valente G; Isidoro C
Cancer Biomark; 2010; 7(1):47-64. PubMed ID: 21045264
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for breast cancer: the search continues.
Alvarez RH; Price JE
Cancer Biol Ther; 2010 Jan; 9(1):31-2. PubMed ID: 20150755
[No Abstract] [Full Text] [Related]
[Next] [New Search]
